NCT03577691

Brief Summary

The trial is a prospective, randomized study to determine the efficacy of training for use of a web based Decision Aid for Hydroxyurea(HU) usage among subjects with Sickle Cell Disease(SCD). Subjects are randomized primarily either to using a web based decision aid with training versus without training. Subjects in each group will be further randomized to 1) subjects receiving pretest surveys; and 2) subjects that do not receive pretest surveys.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Aug 2018

Geographic Reach
1 country

3 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 28, 2018

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 5, 2018

Completed
29 days until next milestone

Study Start

First participant enrolled

August 3, 2018

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 3, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 3, 2019

Completed
Last Updated

July 23, 2019

Status Verified

July 1, 2019

Enrollment Period

11 months

First QC Date

June 28, 2018

Last Update Submit

July 19, 2019

Conditions

Keywords

Blood DisordersHydroxyurea (HU)Decision Aid

Outcome Measures

Primary Outcomes (1)

  • Change in Knowledge Survey score to estimate the impact of use of the Decision Aid with training versus without training in improving knowledge regarding HydroxyUrea for Sickle Cell Disease

    Subjects knowledge will be tested by using a knowledge Survey that was given at baseline and at 4 weeks follow up phone call. It is a 27 True, False or Unsure questionnaire that tests subjects knowledge of understanding risk for severe lung disease (pulmonary hypertension). This test is administered to both groups that are in turn randomized to to receive the pretest AND posttest or just the posttest surveys.

    Baseline and 4 week follow up

Secondary Outcomes (3)

  • Change in decisional conflict scale to estimate the impact of use of the Decision Aid with training versus without training aid on decisional conflict

    Baseline and 4 week follow up

  • Change in decision self efficacy scale to estimate the impact of use of the Decision Aid with training versus without training aid on decisional conflict

    Baseline and 4 week follow up

  • Change in Preparation for Decision Making Scale to estimate the impact of use of the Decision Aid with training versus without training aid on decisional conflict

    Baseline and 4 week follow up

Study Arms (2)

Training for use of web based Decision Aid

EXPERIMENTAL

Subjects will be provided access to the decision aid website and will receive a log-in identification, user password and url at time of consent and will be guided during a 30 minutes training session to use the website. They will ben be asked to continue to peruse the website at home to learn more about hydroxyurea. Participants in each group will be further randomized to 1) pretest surveys and posttest surveys; and 2)only posttest surveys

Other: Training for use of web based Decision AidOther: Pretest surveys and posttest surveysOther: Only posttest surveys

No training for use of web based Decision Aid

PLACEBO COMPARATOR

Subjects will receive a log-in identification, user password and url at time of scheduled appointment for web access. They will not receive training but will be instructed to maneuver through the website and access the information pertaining to hydroxyurea and access the videos for the purposes of learning. Participants will be asked to peruse the website for 30 minutes at time of consent then to continue to access the website at home to learn about hydroxyurea treatment. Participants in each group will be further randomized to 1) pretest surveys and posttest surveys; and 2)only posttest surveys

Other: No training for use of web based Decision AidOther: Pretest surveys and posttest surveysOther: Only posttest surveys

Interventions

Subjects will be guided during a 30 minutes training session to use the website

Training for use of web based Decision Aid

Subjects will not be guided during a 30 minutes training session to use the website

No training for use of web based Decision Aid

Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid. subjects in each group will be randomized to complete pre test and posttest surveys or only posttest surveys that will take 15 mts of time

No training for use of web based Decision AidTraining for use of web based Decision Aid

Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid. subjects in each group will be randomized to complete pretest and posttest surveys or only posttest surveys.

No training for use of web based Decision AidTraining for use of web based Decision Aid

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Individuals with sickle cell disease ages 18 to 80 years, inclusive Or parents of children (ages 9 months to \<18 years) whose child has not started Hydroxyurea
  • Patients who have made a past decision to not obtain treatment with Hydroxyurea or who have not obtained treatment with Hydroxyurea in past 12 months. Or parents of children who have made a past decision to not obtain treatment with Hydroxyurea or who have not obtained treatment with Hydroxyurea in the past 12 months.
  • Patients or parents of children who's doctor identifies the patient/child as someone who should be on Hydroxyurea
  • All participants will be able to comprehend English
  • Subjects will have access to the internet from iPad, smart phone, or personal computer
  • For the cognitive interviews participants will not be eligible to consider hydroxyurea as a treatment option

You may not qualify if:

  • Patient who has already made a decision to begin and has started Hydroxyurea. Or parent who has already made a decision for their child to begin and the child has started Hydroxyurea.
  • Participated in prior Decision Aid study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Grady Health System

Atlanta, Georgia, 30303, United States

Location

Hughes Spalding Children's Hospital

Atlanta, Georgia, 30303, United States

Location

Children's Healthcare of Atlanta

Atlanta, Georgia, 30322, United States

Location

MeSH Terms

Conditions

Anemia, Sickle CellHematologic Diseases

Condition Hierarchy (Ancestors)

Anemia, Hemolytic, CongenitalAnemia, HemolyticAnemiaHemic and Lymphatic DiseasesHemoglobinopathiesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

  • Lakshmanan Krishnamurti, MD

    Emory University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
FACTORIAL
Model Details: Prospective, randomized,controlled, unblinded study
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

June 28, 2018

First Posted

July 5, 2018

Study Start

August 3, 2018

Primary Completion

July 3, 2019

Study Completion

July 3, 2019

Last Updated

July 23, 2019

Record last verified: 2019-07

Locations